Inicio>>Lipids>> P450>>N-Nornuciferine

N-Nornuciferine (Synonyms: Daechualkaloid E, (R)-Nornuciferine, (–)-Nornuciferine, Sanjoinine Ia)

Catalog No.GC36754

La N-nornuciferina es un alcaloide de aporfina en la hoja de loto que inhibe significativamente CYP2D6 con IC50 y Ki de 3,76 y 2,34 μM, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

N-Nornuciferine Chemical Structure

Cas No.: 4846-19-9

Tamaño Precio Disponibilidad Cantidad
5mg
213,00 $
Disponible
10mg
367,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

N-Nornuciferine is an aporphine alkaloid in lotus leaf that significantly inhibits CYP2D6 with IC50 and Ki of 3.76 and 2.34 μM, respectively. IC50: 3.76 μM (CYP2D6)[1]Ki: 2.34 μM (CYP2D6)[1]

The herb of lotus leaves is a commonly used traditional Chinese medicine with a wide range of pharmacological and physiological activities, particularly the reduction of the blood triglyceride and cholesterol levels. N-Nornuciferine strongly inhibits CYP2D6 activity but shows weak or no inhibition of the other four P450 isoenzymes (CYP2C19, CYP3A4, CYP2E1, CYP2C9). N-Nornuciferine competitively inhibits the CYP2D6-catalyzed dextromethorphan o-demethylation with apparent Ki values of 2.34 μM[1].

[1]. Ye LH, et al. Identification and characterization of potent CYP2D6 inhibitors in lotus leaves. J Ethnopharmacol. 2014 Apr 11;153(1):190-6.

Reseñas

Review for N-Nornuciferine

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for N-Nornuciferine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.